For estrogen resistance, TAM primarily inhibits ER action through direct competitive binding to the AF-2 domain of ER; TAM can also disrupt protein-protein interactions between ER and its binding partners and thus inhibit the activity of ER in supporting breast cancer sustainable survival [68,69]. The gene discussed is ESR1; the disease is breast cancer.